Journal of pediatric and adolescent gynecology · 2019
The Use of Norethisterone for the Treatment of Severe Uterine Bleeding in Adolescents: An Audit of Our Experience.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Papapanagiotou Ioannis K, Charamanta Maria, Roidi Stella, Al-Achmar Nikolaos Samer, Soldatou Alexandra, Michala Lina
Аннотация
STUDY OBJECTIVE: The purpose of this prospective study was to assess the effectiveness of norethisterone (NET) in the management of abnormal uterine bleeding (AUB) in adolescents in a tertiary care center.
DESIGN: This was a prospective audit focused on administering high doses of NET in female adolescents with complaints of AUB.
SETTING: We included female adolescents who presented to our Emergency Gynecological Department or Adolescent Gynecological Outpatient Department from October 2016 to January 2019.
PARTICIPANTS: The study included 29 female adolescents aged 11-17 (mean, 13.14) years.
INTERVENTIONS: Patients were administered a daily dose of 10-30 mg, depending on the severity of the condition, bleeding duration, and patient weight.
MAIN OUTCOME MEASURES: Cessation of vaginal bleeding.
RESULTS: Mean age at menarche of our patient sample was 11.4 years (range, 10.7-14 years). AUB presented at a mean time of 24.6 months after menarche (range, 0-79 months). Blood transfusion was deemed necessary in 9 patients. Bleeding stopped at a mean of 46.1 (range, 8-120) hours after onset of treatment with NET. No serious adverse events were reported with NET administration, with only 3 cases of minor side effects.
CONCLUSION: The use of NET is an effective and reliable treatment option among adolescents for whom control of AUB is desired in the acute setting.
DESIGN: This was a prospective audit focused on administering high doses of NET in female adolescents with complaints of AUB.
SETTING: We included female adolescents who presented to our Emergency Gynecological Department or Adolescent Gynecological Outpatient Department from October 2016 to January 2019.
PARTICIPANTS: The study included 29 female adolescents aged 11-17 (mean, 13.14) years.
INTERVENTIONS: Patients were administered a daily dose of 10-30 mg, depending on the severity of the condition, bleeding duration, and patient weight.
MAIN OUTCOME MEASURES: Cessation of vaginal bleeding.
RESULTS: Mean age at menarche of our patient sample was 11.4 years (range, 10.7-14 years). AUB presented at a mean time of 24.6 months after menarche (range, 0-79 months). Blood transfusion was deemed necessary in 9 patients. Bleeding stopped at a mean of 46.1 (range, 8-120) hours after onset of treatment with NET. No serious adverse events were reported with NET administration, with only 3 cases of minor side effects.
CONCLUSION: The use of NET is an effective and reliable treatment option among adolescents for whom control of AUB is desired in the acute setting.